linjc16/ctgov huggingface dataset:
Prospective Relationship Between the Rates of Spontaneous Passage of Distal Ureteral Stones and the Distal Lumen

Study Overview
=================
Brief Summary
-----------------
Patients (female, male, or queer) with ureteral stones (smaller than 1 cm at the widest diameter of the stone) without pyonephrosis, urinary sepsis, or untraceable pain will be enrolled into the study. Ureteral width at the smallest area of the ureter (in most cases UV junction) will be noted during regular ultrasound scans. The ratio of ureteral width to the stone diameter will be correlated with the spontaneous stone passage.

Official Title
-----------------
Prospective Observational Evaluation of the Relationship Between the Rates of Spontaneous Passage of Distal Ureteral Stones and the Diameter of the Most Narrow Part of the Distal Ureter

Conditions
-----------------
Ureter Stone

Intervention / Treatment
-----------------
* Procedure: Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ureteral Stone smaller than 1 cm Volunteer to be enrolled Exclusion Criteria: Pyonephrosis Urinary Sepsis Untraceable Pain

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Passage Observed<br>Enrolled patients whose stone and ureter diameters are obtained and their stone passage was successful during the follow-up. | Procedure: Ultrasound<br>* Enrolled patients underwent ultrasound scan of kidneys, ureters, and the bladder.<br>|
| Passage Not Observed<br>Enrolled patients whose stone and ureter diameters are obtained and their stone passage was not successful during the follow-up. | Procedure: Ultrasound<br>* Enrolled patients underwent ultrasound scan of kidneys, ureters, and the bladder.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Passage | The number of recruited individuals whose ureteral stones are found to be passed by their report and it is confirmed by ultrasound | 3 months |
Rapid Identification of Mycobacteria in Acid-fast Bacilli Smear-positive Respiratory Specimens

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the polymerase chain reaction (PCR)-Reverse Blot Hybridization Assay (REBA) for identification of nontuberculous mycobacteria (NTM) species in acid-fast bacilli (AFB) smear-positive respiratory specimens.

Official Title
-----------------
Rapid Identification of Mycobacteria in Acid-fast Bacilli Smear-positive Respiratory Specimens

Conditions
-----------------
Atypical Mycobacteria, Mycobacterium Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with AFB-smear positive sputum Exclusion Criteria: Non-applicable
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sputum with positive AFB smear<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Results of REBA for identification of NTM species |  | End of study |
Study of Mindfulness-Based Cognitive Therapy

Study Overview
=================
Brief Summary
-----------------
Research aimed at assessing changes in depressogenic thinking and the ability to disengage from depressogenic thinking following Mindfulness-Based Cognitive Therapy

Official Title
-----------------
Toward Identifying the Mechanisms of Action in Mindfulness-Based Cognitive Therapy

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Behavioral: Mindfulness-Based Cognitive Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History of two or more Major Depressive Episodes or history of a Major Depressive Episode lasting at least one year Can speak, read, and understand English Exclusion Criteria: Meet Criteria for Current Major Depressive Episode or are in partial remission BDI-II score above 19 Abuse alcohol or drugs Current Dysthymic Disorder History of: psychosis when not depressed or intoxicated, Mania, Hypomania, Obsessive Compulsive Disorder, Posttraumatic Stress Disorder, Anorexia Nervosa, Bulimia Nervosa

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mindfulness-Based Cognitive Therapy plus treatment as usual<br> | Behavioral: Mindfulness-Based Cognitive Therapy<br>* Mindfulness-Based Cognitive Therapy for the prevention of depressive relapse/recurrence<br>|
| No Intervention: MBCT Waitlist plus Treatment as Usual<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sustained Attention to Response Task |  | zero to four weeks pre-treatment and zero to three weeks post-treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Five Facet Mindfulness Questionnaire |  | zero to four weeks pre-treatment and zero to three weeks post-treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MBCT, Mindfulness-Based Cognitive Therapy, Mindfulness, Meditation, Relapse Prevention, Recurrent Depression, Depression, Major Depressive Disorder
The Imaging Genetic Study of the Core Family of Obsessive-compulsive Disorder (OCD) Patient

Study Overview
=================
Brief Summary
-----------------
To investigate the structural/functional abnormalities and the possible genetic endophenotypes of Obsessive-compulsive disorder (OCD) patients and their core families.

Official Title
-----------------
The Study of Structural and Functional Brain Abnormalities and the Association With the Genetic Polymorphism in the Core Family of OCD Patient

Conditions
-----------------
OCD

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed OCD patient Exclusion Criteria: organic disease other psychiatric disorder

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| controls<br> | |
| OCD patients<br> | |
| OCD parents<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Y-BOCS |  | Y-BOCS |
Predictors of the Metabolic Effect of Sleep Loss

Study Overview
=================
Brief Summary
-----------------
To test whether baseline levels of slow wave activity (SWA) during sleep are lower in obese adults, and even lower in persons with sleep disordered breathing (SDB) compared to lean adults. To compare levels of SWA in individuals in relation to their sleep time, blood pressure, heart rate, and markers of glucose metabolism.

Official Title
-----------------
Predictors of the Metabolic Effect of Sleep Loss

Conditions
-----------------
Apnea, Obstructive Sleep Apnea (OSA), Obesity

Intervention / Treatment
-----------------
* Other: Restriction
* Other: Extension


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy, normal sleepers, lean, overweight, obese, pre menopausal Exclusion Criteria: no shift workers or night-shift workers, no mental health disorders, no acute or chronic health conditions (stable, well controlled hypertension are accepted), no hormonal treatments, no substances that may interfere with sleep, problems with sleep

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Sleep time restriction | Other: Restriction<br>* Time in bed for each subject is restricted by two hours per night for 4 nights<br>|
| Experimental: 2<br>Sleep time extension | Other: Extension<br>* Bedtime is extended by 2 hours per night for 4 nights<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between SWA, sleep duration,sleep architecture, and biomarkers of the metabolic syndrome in lean, obese with and without obstructive sleep apnea. |  | study completion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sleep, Apnea, OSA, obese, middle-aged
Effects of Continuous Noninvasive Arterial Pressure Measurement on Anaesthesia

Study Overview
=================
Brief Summary
-----------------
Continuous noninvasive blood pressure monitoring may help to avoid intraoperative Hypotension or Hypertension

Official Title
-----------------
Impact of Continuous Noninvasive Arterial Blood Pressure Monitoring on Blood Pressure Stability During General Anaesthesia in Orthopedic Patients

Conditions
-----------------
Blood Pressure Stability in General Anaesthesia

Intervention / Treatment
-----------------
* Device: continuous noninvasive blood pressure monitoring ClearSight-Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: orthopedic surgery in general anaesthesia American Society of Anesthesiologists - Physical Status (ASA) 2 or ASA 3 arterial Hypertension Exclusion Criteria: -invasive blood pressure monitoring required

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Continunous blood pressure monitoring<br>Patients receive continuous noninvasive blood pressure monitoring in addition to intermittent monitoring | Device: continuous noninvasive blood pressure monitoring ClearSight-Device<br>* Noninvasive continuous blood pressure monitoring using the volume clamp method (ClearSight-Device)<br>* Other names: ClearSight-Device (Edwards);|
| No Intervention: Intermittent blood pressure monitoring<br>Control group with intermittent blood pressure monitoring | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients with Hypotensive Events in comparison between both groups |  | During induction and maintainance of general anaesthesia (average estimated time = 3 hours) | 
| Dosage of Norepinephrine given to the patient to maintain blood pressure normotensive |  | During induction and maintainance of general anaesthesia (average estimated time = 3 hours) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of acute kidney failure postoperatively |  | during hospital stay after surgical procedure (in average 3 days) |
Exemestane in Advanced and Recurrent Endometrial Carcinoma

Study Overview
=================
Brief Summary
-----------------
A phase II study of Exemestane in Advanced or recurrent endometrial carcinoma Hypothesis: Treatment With Exemestane can give a response rate of at least 30%

Detailed Description
-----------------
Patients With Advanced or recurrent endometrial cancer of endometrioid type were treated With Exemestane tablets 25 mg daily. Patients were grouped according to estrogen receptor status.

Official Title
-----------------
Phase 2 Study of Exemestane in Advanced and Recurrent Endometrial Carcinoma

Conditions
-----------------
Endometrial Cancer

Intervention / Treatment
-----------------
* Drug: Exemestane


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Advanced or recurrent endometrial cancer not considered for treatment modalities apart from hormonal treatment Endometrioid histology Age above 18 years Post menopausal status Performance status 0-2 Informed consent Exclusion Criteria: Congestive heart disease grade III.IV History of thromboembolic signs Other primary hormonal therapy Patients With symptomatic brain metastasis Severe hepatic or renal impairment Pregnancy, lactation or child bearing potential without adequate contraception

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exemestane<br>Exemestane 25 mg daily | Drug: Exemestane<br>* One tablet Exemestane 25 mg daily<br>* Other names: Aromasin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate | Objective response rate within 6 months of treatment | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival | Special attention to progression status at 6 months | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endometrial cancer
A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

Study Overview
=================
Brief Summary
-----------------
PRO 140 2102 is a phase 2b, national, multicenter, randomized, double-blind, placebo-controlled study in order to evaluate the safety and efficacy of PRO 140 (anti-CCR5 monoclonal antibody) administered subcutaneously as an adjunct to a new, optimized, oral antiretroviral regimen in HIV-infected injection drug users with viral rebound and documented poor adherence to the previous antiretroviral regimen.

Official Title
-----------------
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Observed Systemic, Long-Acting, Anti-HIV Treatment With a Monoclonal Anti CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-Infected Injection Drug Users With Viral Rebound and Documented Poor Adherence to the Previous Antiretroviral Regimen

Conditions
-----------------
HIV

Intervention / Treatment
-----------------
* Drug: PRO 140
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Only R5 virus HIV-1 RNA > 1,000 copies/mL but < 100,000 copies/mL CD4+ lymphocyte counts > 100 cells/μL Non-prescription recreational drug use within the previous 6 months Key Exclusion Criteria: Females who are pregnant (positive blood test), lactating, or breastfeeding, or who plan to become pregnant during the study Prior use of any CCR5 entry inhibitors History of any acquired immune deficiency syndrome (AIDS)-defining illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br>PRO 140 | Drug: PRO 140<br>* SC injection<br>|
| Placebo Comparator: Arm 2<br>Placebo | Drug: Placebo<br>* SC injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Specific measure that will be used to determine the effect of the interventions: Percentage of subjects without virologic failure at week 24. | Percentage of subjects without virologic failure at week 24. | 24 Weeks |
Prostate Cancer Survey

Study Overview
=================
Brief Summary
-----------------
There have been calls from patients, payers, healthcare providers, and policy makers for an evaluation of newer, high-cost radiation technologies compared to conventional forms of radiation therapy. National attention has focused on the use of intensity modulated radiation therapy (IMRT) into routine daily clinical practice for prostate cancer. The goal of the present study is to determine whether the type of radiation treatment received by the patients can result in a reduction in patient-relevant side effects following prostate irradiation. The analysis will be performed by obtaining patient answered surveys looking at side effects.

Official Title
-----------------
Identifying Patient-relevant Adverse Events Following Prostate Radiotherapy

Conditions
-----------------
Prostate Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participant is 18 years or older Has been diagnosed with prostate cancer Able to speak and read English Exclusion Criteria: Participant is not being seen for prostate cancer Under the age of 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Survey Group<br>Approximately 300 patients with prostate cancer will be provided a survey investigating their treatment preferences and side effects faced during and after receiving radiation treatment. | |
| Focus Group<br>Approximately 75 participants will participate in a focus group. All participants will have completed radiation treatment and will discuss side effects after having received radiation, as well as their quality of life while receiving radiation. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine patient preference weights for side effect reduction in radiation treatment of prostate cancer | Investigators will use an anonymous survey and results from multiple focus groups to quantify the relative importance/significance of commonly encountered side effects experienced by patients following external beam radiation therapy. We will complete descriptive statistics as a means of understanding the data obtained by survey responses. Additionally, comparative analyses may be undertaken to evaluate differences between different side effects experienced. | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Survey, Focus Group, Treatment Preferences
Beneficial Effects of Preference on Behavior in DOC Patients (COGNICOMA)

Study Overview
=================
Brief Summary
-----------------
Preferred music improves cognitive function in patients with disorders of consciousness (DOC). However, it is still unknown whether it is a general effect of music (because of its acoustic features) or an autobiographical effect (because of its emotional and meaningful contents). The aim of the present study was to investigate the effect of sensory modality (auditory versus olfactory) and preference (preferred versus neutral) of the testing context on the performance of four items from the coma recovery scale-revised

Official Title
-----------------
Beneficial Effects of Preference on Behavior

Conditions
-----------------
Disorders of Consciousness

Intervention / Treatment
-----------------
* Behavioral: sounds and odors


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Disorders of consciousness (Traumatic brain injury, stroke or anoxic encephalopathy) Coma diagnosis (Plum and Posner, 1966), vegetative state (Task Force, 1994) or minimally conscious state (Giacino, Ashwal et al. 2002) Lack of autonomic crisis since one week minimum Medical condition considered stable Patients who do not present hearing loss. Peaks I and II of Brainstem Auditory Evoked Potentials (BAEP) will be normal. Exclusion Criteria: Hearing Problem Uncontrolled Epilepsy Autonomic crises Medical unstable state Pregnant or likely to be (interrogation data) or breastfeeding woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: patients behavior<br>Behavior (motor reaction) to stimuli (sounds and odors) | Behavioral: sounds and odors<br>* presentation of sounds and odors<br>|
| Active Comparator: healthy volunteers behavior<br>Behavior (motor reaction) to stimuli (sounds and odors) | Behavioral: sounds and odors<br>* presentation of sounds and odors<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive Function measured using the Coma Recovery Scale | Improvement of the score following sound stimuli and/or preferred stimuli | within the first 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reaction time | Faster reaction following sound stimuli and/or preferred stimuli | within the first 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vegetative state, minimally conscious state, music, preference